MedStar Authors catalog › Details for: Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy.
Normal view MARC view ISBD view

Intravenous Epoprostenol for Management of Pulmonary Arterial Hypertension during Pregnancy.

by Timofeev, Julia; Ruiz, George; Fries, Melissa H; Driggers, Rita W.
Citation: American journal of perinatology reports. 3(2):71-4, 2013 Oct..Journal: AJP reports.Published: ; 2013ISSN: 2157-7005.Full author list: Timofeev J; Ruiz G; Fries M; Driggers RW.UI/PMID: 24147238.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular Institute | MedStar Washington Hospital CenterDepartment(s): Obstetrics and Gynecology/Maternal-Fetal MedicineActivity type: Journal Article.Medline article type(s): Case ReportsOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1055/s-0033-1338169 (Click here) Abbreviated citation: Am. j. perinatol. reports. 3(2):71-4, 2013 Oct.Abstract: Background Pulmonary arterial hypertension carries a high risk of mortality in pregnancy. Recent advances in treatment may improve disease course and allow for successful management of the pregnancy. Case Report We present the case of a 20-year-old gravida 1, para 0 with diagnosis of severe primary pulmonary hypertension. The patient was managed with epoprostenol (prostacyclin) infusion via an indwelling catheter, which was initiated at 23 weeks' gestation. The dose was adjusted to the patient's symptoms and a successful vaginal delivery was achieved at 36 weeks' gestation. Although maternal postpartum course was uncomplicated, unexplained neonatal demise occurred at 11 days of life. Conclusion Successful management of pulmonary hypertension in pregnancy can be accomplished with a multidisciplinary approach and intensive therapy. Long-term effects of epoprostenol on fetal or neonatal well-being are unknown.

Powered by Koha